Guoqing Chen

Advenchen Laboratories LLC operates as a pharmaceutical company. It focuses on pharmaceutical research and development involving small molecule cancer drug discovery programs. The firm’s proprietary drug development product pipeline has demonstrated anti-tumor activities and therapeutic benefits. The company is headquartered in Moorpark, CA.

Elevar Therapeutics, Inc. engages in the provision of biopharmaceutical services. It offers Rivoceranib, a small-molecule angiogenesis inhibitor in gastric cancer that use in the growth and proliferation in cancer cells. The company was founded by Sung Chul Kim and Soo Whan Choi in 2005 and is headquartered in Salt Lake City, UT.

Tularik, Inc. is engaged in the discovery and development of a broad range of novel and superior orally available medicines that act through the regulation of gene expression. Tularik's scientific platform is focused on three therapeutic areas: cancer, inflammation and metabolic disease. The company was founded in 1991 and is headquartered in South San Francisco, CA.

Igenica Biotherapeutics, Inc. develops therapeutics for the treatment of cancer. It develops antibodies and antibody-drug conjugates (ADCs) for the treatment of cancer. The firm offers recombinant monoclonal antibodies for oncology and cancer treatment. The company was founded by Robert Schreiber and Guoqing Chen in 2008 and is headquartered in Burlingame, CA.